No Data
No Data
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., "A Leader in Novel Neuropsychiatry Therapeutics"
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Strong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management Positioning
Cybin Is Maintained at Buy by Canaccord Genuity
Express News | Cybin Inc : Canaccord Genuity Cuts Target Price to $96 From $114
Cybin Provides Corporate Update On Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In Major Depressive Disorder Expected Imminently; 12-Month Efficacy Data From Phase 2 Study Of CYB003 In MDD Expected In Early Q4 2024; Phase 2...
loading...
No Data
No Data